Join BJS Academy
BJS Academy>Randomized clinical ...>Adjuvant S 1 compare...
Normal View Dyslexic View

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

6 March 2023
Randomized clinical trials HPB
Nakachi K, Ikeda M, Konishi M, Nomura Skatayama H, Kataoka T, et al  on behalf of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).

Lancet 2023; 401: 195-203.

In this study that included 440 procedures, after a median of 45.4 months, adjuvant S-1 therapy given for four cycles improved overall survival from 67.6 to 77.1 per cent, P=0.008.

Comment: A benchmark study for this rare condition, that provides a real hope of improved survival.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct138
Randomized clinical trials
Randomized clinical trials
HPB
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Nakachi K, Ikeda M, Konishi M, Nomura Skatayama H, Kataoka T, et al  on behalf of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).
06032023
Lancet 2023; 401: 195-203.
In this study that included 440 procedures, after a median of 45.4 months, adjuvant S-1 therapy given for four cycles improved overall survival from 67.6 to 77.1 per cent, P=0.008.
Comment: A benchmark study for this rare condition, that provides a real hope of improved survival.
Published on: 6 March 2023
Article ID: rct138

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Kumar M, Patil NS, Mohapatra N, Sindwani G, Dhingra U, Yadav A et al.
Ann Surg 2024; 279: 932-944.

16 August 2024

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!